Jaguar Health, Inc. current report, 31 December 2020

Jaguar Health, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K covers events occurring between December 28, 2020, and January 7, 2021, with the report filed on January 8, 2021. Jaguar Health, Inc. (JAGX) is an emerging growth company incorporated in Delaware, trading on The Nasdaq Capital Market.

Key Financial Metrics and Transactions

The filing details unregistered sales of equity securities used to settle debt obligations rather than reporting standard operating financial metrics such as revenue or cash flow.

  • Shares Issued: 2,663,606 shares of Common Stock were issued in total.
  • Debt Reduction: The issuance resulted in a total reduction of $2,837,689 in the outstanding balance of secured promissory notes.
  • Transaction 1 (Dec 31, 2020): 1,250,000 shares issued for a $1,000,000 debt reduction.
  • Transaction 2 (Jan 4, 2021): 1,413,606 shares issued for a $1,837,689 debt reduction.
  • Pricing: Shares were issued at an effective price per share equal to the market price (Minimum Price under Nasdaq Listing Rule 5635(d)).

Material Changes

As a direct result of the exchange transactions described above, the Company's secured promissory notes issued on May 28, 2019, have been repaid in full and are no longer outstanding. The filing does not provide comparative financial data for prior periods.

Outlook, Risks, and Unusual Items

The shares were issued in reliance on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933. The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the debt-for-equity swap.

Investor Verification Checklist

  • Verify the exact market price per share used for the December 31, 2020, and January 4, 2021, transactions to confirm the implied valuation.
  • Confirm the full repayment status of the secured promissory notes originally issued on May 28, 2019.
  • Review the impact of the 2,663,606 new shares on total outstanding share count and potential dilution.
  • Check subsequent filings for any remaining secured debt obligations.